Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $3,414,000.00 in Stock

by · The Cerbat Gem

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at $75,855,438.40. The trade was a 4.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Nello Mainolfi also recently made the following trade(s):

  • On Tuesday, July 7th, Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00.

Kymera Therapeutics Stock Performance

KYMR opened at $107.39 on Friday. The firm’s fifty day moving average is $114.62 and its two-hundred day moving average is $98.93. The firm has a market cap of $8.93 billion, a PE ratio of -33.14 and a beta of 1.98. Kymera Therapeutics, Inc. has a twelve month low of $55.26 and a twelve month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s revenue was up 465.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.95) EPS. Equities analysts forecast that Kymera Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. BlackRock Inc. acquired a new stake in shares of Kymera Therapeutics in the second quarter valued at approximately $635,067,000. Baker BROS. Advisors LP increased its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Merck & Co. Inc. bought a new stake in Kymera Therapeutics in the 2nd quarter valued at $88,544,161. Finally, Bank of America Corp DE acquired a new stake in Kymera Therapeutics during the 2nd quarter valued at $43,378,000.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KYMR. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research note on Thursday, September 10th. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, August 5th. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Stifel Nicolaus upped their target price on shares of Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Finally, Mizuho increased their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $133.21.

View Our Latest Research Report on Kymera Therapeutics

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.

Recommended Stories